NMN is a direct precursor of NAD+, the metabolic coenzyme that fades with age. It is the molecule the anti-ageing field bet on to simply refill the tank — and the one with more human data than almost anything in this catalogue.
How metabolic research moved from a single receptor to two to three — and what each added hormone receptor changed in the preclinical and trial evidence. A mechanism comparison, with the research-use-only distinctions kept strict.
Two synthetic peptides that are almost always studied as a pair: one mimics ghrelin, the other mimics GHRH. A research primer on how each knocks on the growth-hormone axis — and what the preclinical record actually shows.
5-Amino-1MQ is a small-molecule inhibitor of the enzyme NNMT, studied in cells and obese mice for its effects on the NAD+ and methylation economy of fat tissue. Here is what the preclinical record actually shows — and where it stops.
A four-letter peptide carries a decades-old case of mistaken identity. A 2026 re-examination argues the famous dose was never Epitalon’s at all — and that the difference is a lesson in why what is in the vial matters more than the label on it.
Retatrutide (LY3437943) is a single engineered peptide built to pull three metabolic levers at once. Here is what the science actually shows — and why a research-grade compound is not the same thing as an approved medicine.
Cookies
We use strictly necessary cookies to run the store. With your consent we also use analytics (order attribution) and marketing (Omnisend) cookies. Read our Cookie Policy.
